A Study of Blood Based Biomarkers for Pancreas Adenocarcinoma
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorMemorial Sloan Kettering Cancer Center
About this trial
The purpose of this study is to develop a minimally invasive test to diagnose pancreatic cancer at early stages of disease and monitor response to treatment.
Eligibility criteria
Qualifiers
Radiological, histological or cytological confirmed diagnosis of locally advanced or metastatic pancreatic adenocarcinoma by the enrolling institution
Patient planning to receive systemic treatment
Hemoglobin > 8
ECOG performance status 0-2
Disqualifiers
Prior chemotherapy or radiation therapy for pancreatic cancer within the last 3 months in the localized setting
Active second malignancy, unless low grade malignancy
Any medical or psychiatric condition that may interfere with ability to comply with protocol procedures
Neoadjuvant chemotherapy or radiation therapy is planned
Trial design
Treatments tested in this trial
- Blood Draw
- Tumor Tissue Collection
- Cyst Fluid
Treatment groups
700 Participants
are divided into 4 treatment groupsLocations
13Israel
Sha'are Zedek Medical Center91031, Jerusalem Israel
Weizmann Institute of Science Rehovot Israel
Sheba Medical Center Tel Litwinsky Israel
United States
Memorial Sloan Kettering Monmouth (All protocol activities)07748, MiddletownNew Jersey, United States
Sponsors and collaborators
Memorial Sloan Kettering Cancer Center
Lead sponsor
Sheba Medical Center
Collaborator
Weill Medical College of Cornell University
Collaborator
Weizmann Institute of Science
Collaborator
Source ClinicalTrials.gov